Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19
- PMID: 33320258
- PMCID: PMC7953960
- DOI: 10.1093/ntr/ntaa187
Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19
Abstract
This commentary addresses the state of the evidence on tobacco products, nicotine, and COVID-19. The evidence of the effects of smoking on respiratory infections and the immune system in general are examined and the current understanding of tobacco products and risk for SARS-CoV-2 infection and the course of COVID-19 is addressed.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.
References
- 
    - Simons D, Shahab L, Brown J, Perski O.. The Association of Smoking Status with SARS-CoV-2 Infection, Hospitalisation and Mortality from COVID-19: A Living Rapid Evidence Review with Bayesian Meta-analyses (Version 7). Qeios; 2020. https://www.qeios.com/read/UJR2AW.8. Accessed September 9, 2020. - PMC - PubMed
 
- 
    - USDHHS. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
 
- 
    - Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza—systematic review. J Infect. 2019;79(5):401–406. - PubMed
 
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
- Medical
- Miscellaneous
 
        